BIO Ventures for Global Health

North Yelm, WA, United States

BIO Ventures for Global Health

North Yelm, WA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | May 17, 2017
Site: www.businesswire.com

SEATTLE--(BUSINESS WIRE)--BIO Ventures for Global Health (BVGH), which enlists the capabilities of the biotechnology and pharmaceutical industries to tackle critical global health needs, today announced it will expand its programs to address the emerging cancer crisis in Africa. The African Access Initiative (AAI) will provide affordable, sustainable access to cancer therapeutics, enhance healthcare capacity, and foster cancer research in Africa. BVGH will launch its new initiative at the Biotechnology Innovation Organization (BIO) International Convention in San Diego on June 21, 2017. “The global health community has made important headway in tackling infectious diseases such as malaria in Africa, yet we are seeing an alarming rise in cancer and other non-communicable diseases,” said Jennifer Dent, President of BVGH. “The BVGH team will leverage our strong industry relationships, African networks, and capacity-building programs to help local healthcare professionals gain access to the cancer medicines they need and deliver educational, diagnostic, and treatment services in their communities.” “Healthcare has come a long way in Africa, but as we make inroads into some of the infectious diseases that have so plagued the continent, we must refocus our vision on the non-communicable diseases, especially cancer, that affects millions of people globally,” said Professor and Honorable Minister of Health, Isaac Adewole, Nigeria. “We must take action now to build infrastructure and develop sustainable means to provide access to cancer treatments in Africa. Our partnership with BVGH is an important step down this path.” Cancer kills 50% more Africans than malaria. GLOBOCAN reported the number of Africans who died from cancer in 2015 was 635,404. By comparison, malaria killed 394,680 Africans according to the World Health Organization (WHO) World Malaria Report 2016. The WHO expects cancer deaths in Africa will nearly double in the next two decades, while malaria is projected to continue to decline on the continent. African healthcare leaders are turning their attention to cancer and non-communicable diseases as they see the rise in cancer cases is already overwhelming many existing healthcare systems. Most African countries do not even have adequate radiation centers to treat patients. Some countries have none and lack the specialized skills necessary to deliver radiation therapy. Dramatic disparities in patient outcomes are the norm in Africa compared to middle and higher income countries. For example, 5-year net survival from breast cancer is 90% in the US, vs. 12% in Gambia. "Understanding Africa's cancer crisis is the first step in finding innovative ways of overcoming the current health systems' challenges on the continent," said Dr. Cristina Stefan, president-elect of the African Organization for Research and Training in Cancer (AORTIC). "Partnerships and collaboration with international organizations are essential in advancing and sustaining a better health care with access to oncology medicine for all Africans, as well as for responsible teaching, training and research." The initial phase of AAI will involve one to three hospitals in each of six African countries – Cameroon, Côte d'Ivoire, the Democratic Republic of the Congo, Kenya, Nigeria, and Senegal. BVGH will assess the cancer treatment and R&D needs of each participating hospital and country; engage pharmaceutical and biotechnology companies with complementary capabilities, priorities and interests; and broker innovative partnership and custom pricing agreements among the hospitals, governments, and companies to address the identified needs. Details of the AAI program along with a joint BVGH/AORTIC white paper on the state of cancer care in Africa will be presented at the BIO meeting in June. BVGH will also be hosting its third annual Africa Pavilion at the BIO Convention, featuring representatives from AORTIC, the European & Developing Countries Clinical Trials Partnership (EDCTP) Networks of Excellence, the East African Health Research Commission (EAHRC), and leading African research organizations. Participation in the 2017 Africa Pavilion will represent 24 African countries. BVGH is a results-oriented nonprofit organization based in Seattle, Washington, USA whose mission is to engage private industry in global health initiatives. BVGH engages global health stakeholders in partnerships to accelerate the development of new drugs, vaccines, and diagnostics that address the unmet medical needs of the developing world. Working at the crossroads of the biopharmaceutical industry and global health, BVGH creates customized programs that fit the needs and capacity of partners and impact health in measurable ways. About the African Organization for Research and Training in Cancer (AORTIC) AORTIC seeks to become the Continent’s pre-eminent non-profit organisation working for cancer control. AORTIC will achieve this through the facilitation of research and training as well as the provision of relevant and accurate information on the prevention, early diagnosis, treatment, and palliation of cancer. Our organisation is dedicated to providing all Africans with these benefits, as well as to increasing public awareness of cancer and reducing the stigma associated with it.


News Article | May 22, 2017
Site: www.marketwired.com

BOSTON, MA--(Marketwired - May 22, 2017) - Pieris Pharmaceuticals, Inc. ( : PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that James Geraghty has joined the Company's Board of Directors, bringing the total number of directors to eight. Mr. Geraghty is an industry leader with 30 years of strategic and leadership experience, including more than 20 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. Until 2016, Mr. Geraghty was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture and company-formation fund, and previously served as Senior Vice President, North America Strategy and Business Development at Sanofi, which he joined upon its acquisition of Genzyme. Mr. Geraghty spent 20 years at Genzyme, where his roles included Senior Vice President International Development, President of Genzyme Europe, and General Manager of Genzyme's cardiovascular business. Mr. Geraghty also oversaw Genzyme's Humanitarian Assistance for Neglected Diseases (HAND) program, under which the company supported innovative development programs on a non-commercial basis. Mr. Geraghty is Chairman of the Board of Idera Pharmaceuticals and Juniper Pharmaceuticals and serves on the Board of Voyager Therapeutics and Fulcrum Therapeutics. He is also a member of the BIO Ventures for Global Health Board of Directors. He started his career in healthcare strategy consulting at Bain and Company. A graduate of the Yale Law School, Mr. Geraghty holds a M.S. from the University of Pennsylvania and a B.A. from Georgetown University. Commenting on the announcement Mr. Geraghty stated, "With the upcoming advancement of Pieris' lead immuno-oncology and respiratory drug candidates into the clinic and its recent strategic partnerships, Pieris is poised to make significant contributions to patients with critical unmet medical needs. I look forward to working with Steve and the rest of the team during this exciting time for Pieris." "It's a great pleasure to welcome Jim to the Pieris board," said Stephen Yoder, President and CEO of Pieris. "I'm confident Jim's strong life sciences pedigree and extensive background in company building will positively impact our Company as we continue our strong growth trajectory." Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin is a registered trademark of Pieris. For more information, visit www.pieris.com. This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; the timing and progress of our studies, our liquidity and ability to fund our future operations; our ability to achieve certain milestones and receive future milestone or royalty payments; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and the Company's Quarterly Reports on Form 10-Q.


Ramamoorthi R.,BIO Ventures for Global Health | Graef K.M.,BIO Ventures for Global Health | Dent J.,BIO Ventures for Global Health
International Journal for Parasitology: Drugs and Drug Resistance | Year: 2014

Neglected tropical diseases (NTDs), malaria, and tuberculosis have a devastating effect on an estimated 1.6. billion people worldwide. The World Intellectual Property Organization (WIPO) Re:Search consortium accelerates the development of new drugs, vaccines, and diagnostics for these diseases by connecting the assets and resources of pharmaceutical companies, such as compound libraries and expertise, to academic or nonprofit researchers with novel product discovery or development ideas. As the WIPO Re:Search Partnership Hub Administrator, BIO Ventures for Global Health (BVGH) fields requests from researchers, identifies Member organizations able to fulfill these requests, and helps forge mutually beneficial collaborations. Since its inception in October 2011, WIPO Re:Search membership has expanded to more than 90 institutions, including leading pharmaceutical companies, universities, nonprofit research institutions, and product development partnerships from around the world. To date, WIPO Re:Search has facilitated over 70 research agreements between Consortium Members, including 11 collaborations focused on anthelmintic drug discovery. © 2014 Australian Society for Parasitology.


Ramamoorthi R.,BIO Ventures for Global Health | Graef K.M.,BIO Ventures for Global Health | Krattiger A.,World Intellectual Property Organization | Dent J.C.,BIO Ventures for Global Health
Chemical Reviews | Year: 2014

The World Intellectual Property Organization (WIPO), BIO Ventures for Global Health (BVGH), and eight leading pharmaceutical companies, Alnylam, AstraZeneca, Eisai, GlaxoSmithKline (GSK), MSD, Novartis, Pfizer, and Sanofi joined forces to establish the WIPO Re:Search consortium. WIPO Re:Search seeks to accelerate the development of new drugs, vaccines, and diagnostics for NTDs, malaria, and tuberculosis by connecting the resources of private industry to academic and nonprofit researchers with novel product discovery or development ideas for these diseases. Through WIPO Re:Search, researchers are exploring how natural products may lead to the development of novel tuberculosis treatments. Researchers at the National Institute of Immunology (NII) in New Delhi, India, are utilizing the GSK PKIS1 to examine the essential molecular mechanisms of M. tuberculosis cell wall synthesis. By providing nonprofit and academic researchers working on neglected diseases with the opportunity to access compounds and expertise from pharmaceutical companies, WIPO Re:Search is opening new doors and creating additional avenues for product development for diseases of poverty.


Ramamoorthi R.,BIO Ventures for Global Health | Graef K.M.,BIO Ventures for Global Health | Dent J.,BIO Ventures for Global Health
Future Medicinal Chemistry | Year: 2015

Schistosomiasis, one of 17 diseases deemed to be neglected by the World Health Organization, has received little attention from the biopharmaceutical industry. Due to this, only a handful of drugs have been developed to treat schistosomiasis, with only one, praziquantel, used in most endemic regions. Growing concern over resistance coupled with praziquantel's incomplete efficacy across all stages of the Schistosoma platyhelminth life cycle highlights the urgent need for new drugs. The WIPO Re:Search consortium is a platform whereupon biopharmaceutical company compounds are being repurposed to efficiently and cost-effectively develop new drugs for neglected diseases such as schistosomiasis. This article summarizes recent clinical-stage efforts to identify new antischistosomals and highlights biopharmaceutical company compounds with potential for repurposing to treat schistosomiasis. © 2015 Future Science Ltd.

Loading BIO Ventures for Global Health collaborators
Loading BIO Ventures for Global Health collaborators